Global CRO Icon has launched the Firecrest Patient Portal. This portal enables patients to view clinical trial information and is specifically designed to enhance the patients’ understanding of treatment before consenting to participate at an investigator site.

The Patient Portal solution is a component of Icon’s new informatics hub designed to enhance the engagement of patient populations in the development process and is in line with ICH E6 guidance, which recommends patients receive “ample time” to review consent materials and ask follow-up questions.

“The opportunity for education about the trial, before a face-to-face meeting with their doctor, helps patients make truly informed decisions about participation,” said Frances Abeton, vice president, Firecrest at Icon. 

“Improved patient comprehension of a trial can reflect positively in patients’ relationships with investigators and subsequently lead to better recruitment and retention rates. As drug developers begin adopting electronic informed consent platforms improved regulatory-compliant education will be crucial. The Firecrest Patient Portal is a centralized solution for patients, investigators and study staff, making it easier for all involved to interact and stay informed,” said Abeton.

Patients using the Firecrest Patient Portal can find active trials, complete pre-screening questionnaires and select a convenient study location. As the Patient Portal is integrated with Icon’s Firecrest Investigator Portal, investigators can engage directly with patients that have shown interest, schedule visits, and examine live analytics about the materials reviewed by a patient. Patients can read visit-by-visit guides and, as the trial progresses, they can return to the portal to review updates or notifications specific to them. They also will be able to register interest in future clinical trials that will support patient access for upcoming trials.

The Firecrest Patient Portal can be customized in any language, adapted to country specific requirements, and branded as required by sponsors.